Acute myeloid leukemia with deletion 9q within a noncomplex karyotype is associated with CEBPA loss-of-function mutations

Genes Chromosomes and Cancer

Volumn 42, Issue 4, 2005, Pages 427-432

  Fröhling, Stefan ^a   Schlenk, Richard F ^a   Krauter, Jürgen ^b   Thiede, Christian ^c   Ehninger, Gerhard ^c   Haase, Detlef ^d   Harder, Lana ^e   Kreitmeier, Sylvia ^a   Scholl, Claudia ^a   Caligiuri, Michael A ^f   Bloomfield, Clara D ^f   Döhner, Hartmut ^a   Döhner, Konstanze ^a  

^a UNIVERSITY HOSPITAL ULM   (Germany)

^b HANNOVER MEDICAL SCHOOL   (Germany)

^c UNIVERSITY HOSPITAL CARL GUSTAV CARUS   (Germany)

^d UNIVERSITY MEDICAL CENTER GÖTTINGEN   (Germany)

^e UNIVERSITY OF KIEL   (Germany)

^f OHIO STATE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CCAAT ENHANCER BINDING PROTEIN ALPHA; TRANSCRIPTION FACTOR;

ACUTE GRANULOCYTIC LEUKEMIA; ADOLESCENT; ADULT; AGED; ARTICLE; CHROMOSOME 9Q; CONTROLLED STUDY; DISEASE ASSOCIATION; FEMALE; GENE DELETION; GENE MUTATION; HUMAN; KARYOTYPE; MAJOR CLINICAL STUDY; MALE; NUCLEOTIDE SEQUENCE; PATHOGENESIS; PREVALENCE; PRIORITY JOURNAL;

ACUTE DISEASE; ADOLESCENT; ADULT; BASE SEQUENCE; CHROMOSOME DELETION; CHROMOSOMES, HUMAN, PAIR 9; COHORT STUDIES; DNA PRIMERS; HUMANS; LEUKEMIA, MYELOID; MIDDLE AGED; MUTATION; TRANSCRIPTION FACTORS;

EID: 13944257378     PISSN: 10452257     EISSN: None     Source Type: Journal    
DOI: 10.1002/gcc.20152     Document Type: Article

References (21)

1. Byrd JC, Mrózek K, Dodge RK, Carroll AJ, Edwards CG, Arthur DC, Pettenati MJ, Patil SR, Rao KW, Watson MS, Koduru PR, Moore JO, Stone RM, Mayer RJ, Feldman EJ, Davey FR, Schiffer CA, Larson RA, Bloomfield CD. 2002. Pretreatment cytogenetic abnormalities are predictive of induction success, cumulative incidence of relapse, and overall survival in adult patients with de novo acute myeloid leukemia: results from Cancer and Leukemia Group B (CALGB 8461). Blood 100:4325-4336.
2. Cilloni D, Carturan S, Gottardi E, Messa F, Messa E, Fava M, Diverio D, Guerrasio A, Lo-Coco F, Saglio G. 2003. Down-modulation of the C/EBPalpha transcription factor in core binding factor acute myeloid leukemias. Blood 102:2705-2706.
3. Daly SB, Wainscoat JS, Side LE, Levy ER, Kusec R, Kasprzyk A, Gama SMT, Humphray SJ, Boultwood J, Peniket AJ. 2001. Physical and transcriptional characterization of the commonly deleted region in del(9q) AML. Blood 98:560a.
4. Döhner K, Tobis K, Ulrich R, Fröhling S, Benner A, Schlenk RF, Döhner H. 2002. Prognostic significance of partial tandem duplications of the MLL gene in adult patients 16 to 60 years old with acute myeloid leukemia and normal cytogenetics: a study of the Acute Myeloid Leukemia Study Group Ulm. J Clin Oncol 20:3254-3261.
5. Downing JR, Head DR, Curcio-Brint AM, Hulshof MG, Motroni TA, Raimondi SC, Carroll AJ, Drabkin HA, Willman C, Theil KS, Civin CI, Erickson P. 1993. An AML1/ETO fusion transcript is consistently detected by RNA-based polymerase chain reaction in acute myelogenous leukemia containing the (8;21)(q22;q22) translocation. Blood 81:2860-2865.
6. Fröhling S, Schlenk RF, Breitruck J, Benner A, Kreitmeier S, Tobis K, Döhner H, Döhner K. 2002a. Prognostic significance of activating FLT3 mutations in younger adults (16 to 60 years) with acute myeloid leukemia and normal cytogenetics: a study of the AML Study Group Ulm. Blood 100:4372-4380.
7. Fröhling S, Skelin S, Liebisch C, Scholl C, Schlenk RF, Döhner H, Döhner K. 2002b. Comparison of cytogenetic and molecular cytogenetic detection of chromosome abnormalities in 240 consecutive adult patients with acute myeloid leukemia. J Clin Oncol 20:2480-2485.
8. Fröhling S, Schlenk RF, Stolze I, Bihlmayr J, Benner A, Kreitmeier S, Tobis K, Döhner H, Döhner K. 2004. CEBPA mutations in younger adults with acute myeloid leukemia and normal cytogenetics: prognostic relevance and analysis of cooperating mutations. J Clin Oncol 22:624-633.
9. Gombart AF, Hofmann WK, Kawano S, Takeuchi S, Krug U, Kwok SH, Larsen RJ, Asou H, Miller CW, Hoelzer D, Koeffler HP. 2002. Mutations in the gene encoding the transcription factor CCAAT/enhancer binding protein alpha in myelodysplastic syndromes and acute myeloid leukemias. Blood 99:1332-1340.
10. Grimwade D, Walker H, Oliver F, Wheatley K, Harrison C, Harrison G, Rees J, Hann I, Stevens R, Burnett A, Goldstone A. 1998. The importance of diagnostic cytogenetics on outcome in AML: analysis of 1, 612 patients entered into the MRC AML 10 trial. The Medical Research Council Adult and Children's Leukaemia Working Parties. Blood 92:2322-2333.
11. Kiyoi H, Naoe T, Nakano Y, Yokota S, Minami S, Miyawaki S, Asou N, Kuriyama K, Jinnai I, Shimazaki C, Akiyama H, Saito K, Oh H, Motoji T, Omoto E, Saito H, Ohno R, Ueda R. 1999. Prognostic implication of FLT3 and N-RAS gene mutations in acute myeloid leukemia. Blood 93:3074-3080.
12. Lodie TA, Radomska HS, Donato JD, Johansen LM, Adra C, Pabst T, Behre GB, Hiddemann W, Rego E, Pandolfi PP, Pelicci PG, Tenen DG. 1999. PML/RARα induces ATRA-sensitive delocalization of the critical granulocytic differentiation factor C/EBPα to a microspeckled nuclear pattern in t(15;17) APL. Blood 94(Suppl 1):692a.
13. Mrózek K, Prior TW, Edwards C, Marcucci G, Carroll AJ, Snyder PJ, Koduru PR, Theil KS, Pettenati MJ, Archer KJ, Caligiuri MA, Vardiman JW, Kolitz JE, Larson RA, Bloomfield CD. 2001. Comparison of cytogenetic and molecular genetic detection of t(8;21) and inv(16) in a prospective series of adults with de novo acute myeloid leukemia: a Cancer and Leukemia Group B Study. J Clin Oncol 19:2482-2492.
14. Pabst T, Mueller BU, Harakawa N, Schoch C, Haferlach T, Behre G, Hiddemann W, Zhang DE, Tenen DG. 2001a. AML1-ETO downregulates the granulocytic differentiation factor C/EBPalpha in t(8;21) myeloid leukemia. Nat Med 7:444-451.
15. Pabst T, Mueller BU, Zhang P, Radomska HS, Narravula S, Schnittger S, Behre G, Hiddemann W, Tenen DG. 2001b. Dominant-negative mutations of CEBPA, encoding CCAAT/enhancer binding protein-alpha (C/EBPalpha), in acute myeloid leukemia. Nat Genet 27:263-270.
16. Preudhomme C, Sagot C, Boissel N, Cayuela JM, Tigaud I, de Botton S, Thomas X, Raffoux E, Lamandin C, Castaigne S, Fenaux P, Dombret H. 2002. Favorable prognostic significance of CEBPA mutations in patients with de novo acute myeloid leukemia: a study from the Acute Leukemia French Association (ALFA). Blood 100:2717-2723.
17. Snaddon J, Smith ML, Neat M, Cambal-Parrales M, Dixon-McIver A, Arch R, Amess JA, Rohatiner AZ, Lister TA, Fitzgibbon J. 2003. Mutations of CEBPA in acute myeloid leukemia FAB types M1 and M2. Genes Chromosomes Cancer 37:72-78.
18. Steudel C, Wermke M, Schaich M, Schakel U, Illmer T, Ehninger G, Thiede C. 2003. Comparative analysis of MLL partial tandem duplication and FLT3 internal tandem duplication mutations in 956 adult patients with acute myeloid leukemia. Genes Chromosomes Cancer 37:237-251.
19. Tenen DG, Hromas R, Licht JD, Zhang DE. 1997. Transcription factors, normal myeloid development, and leukemia. Blood 90:489-4519.
20. Thiede C, Steudel C, Mohr B, Schaich M, Schakel U, Platzbecker U, Wermke M, Bornhauser M, Ritter M, Neubauer A, Ehninger G, Illmer T. 2002. Analysis of FLT3-activating mutations in 979 patients with acute myelogenous leukemia: association with FAB subtypes and identification of subgroups with poor prognosis. Blood 99:4326-4335.
21. Van Waalwijk Van Doorn-Khosrovani SB, Erpelinck C, Meijer J, van Oosterhoud S, van Putten WL, Valk PJ, Berna Beverloo H, Tenen DG, Löwenberg B, Delwel R. 2003. Biallelic mutations in the CEBPA gene and low CEBPA expression levels as prognostic markers in intermediate-risk AML. Hematol J 4:31-40.